ADMA Biologics, Inc. (NASDAQ:ADMA) Short Interest Up 5.3% in August

ADMA Biologics, Inc. (NASDAQ:ADMA) saw a significant increase in short interest in August. As of August 31st, there was short interest totalling 9,500,000 shares, an increase of 5.3% from the August 15th total of 9,020,000 shares. Based on an average trading volume of 3,700,000 shares, the short-interest ratio is presently 2.6 days.

ADMA Biologics Stock Performance

ADMA opened at $18.71 on Wednesday. The firm has a fifty day moving average price of $15.33 and a 200 day moving average price of $10.71. ADMA Biologics has a 1 year low of $3.06 and a 1 year high of $19.34. The stock has a market cap of $4.34 billion, a P/E ratio of -935.50 and a beta of 0.61. The company has a debt-to-equity ratio of 0.74, a current ratio of 6.87 and a quick ratio of 2.80.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.05. The firm had revenue of $107.20 million during the quarter, compared to analyst estimates of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. ADMA Biologics’s revenue for the quarter was up 78.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.02) EPS. Equities research analysts anticipate that ADMA Biologics will post 0.49 earnings per share for the current year.

Insider Buying and Selling at ADMA Biologics

In other news, CEO Adam S. Grossman sold 236,889 shares of the stock in a transaction on Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the completion of the sale, the chief executive officer now owns 2,059,726 shares in the company, valued at approximately $36,436,552.94. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In related news, CEO Adam S. Grossman sold 236,889 shares of the company’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the transaction, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at approximately $36,436,552.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, COO Kaitlin M. Kestenberg-Messina sold 24,150 shares of the business’s stock in a transaction dated Friday, August 30th. The stock was sold at an average price of $16.90, for a total value of $408,135.00. Following the sale, the chief operating officer now owns 449,088 shares in the company, valued at approximately $7,589,587.20. The disclosure for this sale can be found here. Insiders sold a total of 466,900 shares of company stock worth $8,224,121 over the last three months. Corporate insiders own 3.70% of the company’s stock.

Institutional Investors Weigh In On ADMA Biologics

Several institutional investors and hedge funds have recently added to or reduced their stakes in ADMA. Victory Capital Management Inc. raised its position in shares of ADMA Biologics by 23.0% during the 4th quarter. Victory Capital Management Inc. now owns 29,192 shares of the biotechnology company’s stock worth $132,000 after purchasing an additional 5,465 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of ADMA Biologics by 1.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,636,703 shares of the biotechnology company’s stock valued at $7,398,000 after acquiring an additional 27,357 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of ADMA Biologics by 49.8% in the fourth quarter. BNP Paribas Financial Markets now owns 290,605 shares of the biotechnology company’s stock worth $1,314,000 after acquiring an additional 96,653 shares during the last quarter. Principal Financial Group Inc. boosted its stake in shares of ADMA Biologics by 17.7% in the fourth quarter. Principal Financial Group Inc. now owns 158,634 shares of the biotechnology company’s stock worth $717,000 after acquiring an additional 23,844 shares during the last quarter. Finally, Oxford Asset Management LLP acquired a new position in ADMA Biologics in the 4th quarter valued at $83,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Wall Street Analysts Forecast Growth

ADMA has been the topic of several research reports. Mizuho increased their price target on shares of ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, June 20th. Cantor Fitzgerald raised their target price on shares of ADMA Biologics from $15.00 to $20.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Finally, HC Wainwright increased their price target on ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. One equities research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $15.50.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.